Sibutramine (Reductil) - information from MHRA

The European Medicines Agency (EMA) has completed a review of sibutramine (Reductil, a treatment for obesity) after new study data raised concerns about its cardiovascular safety. The review has found that the benefits of sibutramine do not outweigh the risks of cardiovascular reactions in clinical use. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended suspension of the marketing authorisation for this medicine across the European Union. Further details can be found below; this information was sent to healthcare professionals through the NHS Central Alerting System on 21 January. Further information will also be available at:

http://www.mhra.gov.uk/NewsCentre/CON068470

http://www.ema.europa.eu/

Further information (pdf) (67kb)